Prognostic index for patients with parotid carcinoma |
| |
| Authors: | Vincent Vander Poorten MD PhD Augustinus Hart MSc Tom Vauterin MD Gert Jeunen MD Joseph Schoenaers MD DDS Marc Hamoir MD PhD Alphonsus Balm MD PhD Eberhard Stennert MD PhD Orlando Guntinas‐Lichius MD PhD Pierre Delaere MD PhD |
| |
| Affiliation: | 1. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals, Leuven, Belgium;2. Leuven Cancer Institute, Leuven, Belgium;3. European Salivary Gland Society;4. Fax: (011) 003216332335;5. Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, The Netherlands;6. Department of Oral and Maxillofacial Surgery, University Hospitals, Leuven, Belgium;7. Department of Otorhinolaryngology, Head and Neck Surgery, St. Luc University Clinics, Brussels, Belgium;8. Department of Head and Neck Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands;9. Department of Otorhinolaryngology, Head and Neck Surgery, Cologne University Clinic, Cologne, Germany;10. Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Clinic, Jena, Germany |
| |
| Abstract: | ![]()
BACKGROUND: Prognostic indices for recurrence‐free interval in patients with parotid carcinoma were developed and validated in a nationwide database. International validation would increase generalizability. METHODS: In a Belgian‐German database that contained 237 consecutive patients with parotid carcinoma, a pretreatment prognostic index (PS1) and a post‐treatment prognostic index (PS2) were validated by calculating both indices for each patient, comparing coefficients, constructing survival curves, calculating the concordance measure C, and performing Wald tests for scale and weight optimization of included variables and for the possible inclusion of new variables. RESULTS: Sixty‐nine percent of patients (standard error, 5%) were disease free at 5 years. The defined cutoff points for PS1 resulted in 5‐year disease‐free rates from 94% (PS1 = 1) to 42% (PS1 = 4), and the cutoff points for PS2 resulted in 5‐year disease‐free rates from 93% (PS2 = 1) to 40% (PS2 = 4). Concordance measure C was good with 0.74 for both PS1 and PS2. Neither index could be improved statistically using this international database. There was some evidence that additional inclusion of the variable ‘number of positive lymph nodes in the neck dissection specimen’ could enhance the prognostic power of PS2. CONCLUSIONS: The prognostic indices performed adequately in this validation sample. Prospective generalized use seems to be well supported. Cancer 2009. © 2009 American Cancer Society. |
| |
| Keywords: | salivary gland neoplasm parotid carcinoma prognostic factors prognostic index validation |
|
|
